OpenLegislation

Paragraph 56C Signal management processF1

England, Wales and Scotland

(1)

For the purposes of these Regulations, “signal management process” means a process for performing active surveillance of pharmacovigilance data for veterinary medicinal products in order to assess the pharmacovigilance data and determine whether there is any change to the benefit-risk balance of those veterinary medicinal products, with a view to detecting risks to animal or public health or protection of the environment.

(2)

A signal management process must consist of tasks of signal detection, validation, confirmation, analysis and prioritisation, assessment and recommendation for action.

(3)

A signal management process must be capable of identifying, at a minimum, in relation to a product—

(a)

a sudden and unexpected increase in the number of adverse events;

(b)

an unexpected increase in the frequency of a known clinical sign;

(c)

a new clinical sign;

(d)

reports in scientific literature of any of the matters mentioned in paragraphs (a) to (c).

Annotations

Textual amendments

F1

Sch. 1 paras. 56-56C substituted for Sch. 1 para. 56 (E.W.S.) (17.5.2024) by The Veterinary Medicines (Amendment etc.) Regulations 2024 (S.I. 2024/567), regs. 1(1), 68

Notes on Schedule 1

Textual amendments

F1

Words in Sch. 1 heading inserted (E.W.S.) (31.12.2020) by The Veterinary Medicines and Residues (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1461), regs. 1(2)(b), 4(7)(a)

F2

Words in Sch. 1 heading inserted (N.I.) (31.12.2020) by The Animals (Health, Identification, Trade and Veterinary Medicines) (Amendment) (EU Exit) Regulations (Northern Ireland) 2020 (S.R. 2020/353), regs. 1(3), 10(13)(a)